Researchers caution against off-label use of Multaq

Researchers published a study in the Journal of the American College of Cardiology suggesting use of Multaq dronedarone from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) should be limited to second- or third-line therapy for atrial fibrillation (AF) in cases where amiodarone is effective but not tolerated. The authors stated that data from several studies, including the Phase III ANDROMEDA trial, showed that Multaq was about half as efficacious as amiodarone but may offer slightly better safety in certain patient populations. The authors conclude that more studies of Multaq and amiodarone with longer follow-up are needed. ...